gefitinib has been researched along with Psoriasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Bamias, A; Efstathiou, E; Stratigos, A; Zorzou, MP | 1 |
2 other study(ies) available for gefitinib and Psoriasis
| Article | Year |
|---|---|
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Recurrence; Severity of Illness Index | 2004 |